We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-1.74%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.74B
AUM Growth
+$339M
Cap. Flow
-$310M
Cap. Flow %
-11.3%
Top 10 Hldgs %
45.15%
Holding
404
New
120
Increased
93
Reduced
80
Closed
88

Top Buys

Rank Stock Value
1
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$23.4M
2
XOM icon
ExxonMobil
XOM
+$15.3M
3
PXD
Pioneer Natural Resource Co.
PXD
+$12.1M
4
MRK icon
Merck
MRK
+$9.03M
5
BPMC
Blueprint Medicines
BPMC
+$8.62M

Top Sells

Rank Stock Value
1
TPST icon
Tempest Therapeutics
TPST
+$53.9M
2
AGN
Allergan plc
AGN
+$33.8M
3
IWM icon
iShares Russell 2000 ETF
IWM
+$24.7M
4
MBLY
Mobileye N.V.
MBLY
+$7.21M
5
MNKD icon
MannKind Corp
MNKD
+$5.7M

Sector Composition

Rank Sector Weight
1 Healthcare 8.27%
2 Energy 1.27%
3 Technology 0.21%
4 Communication Services 0.15%
5 Industrials 0.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADYX
226
DELISTED
Adynxx Inc
ADYX
$791K 0.03%
+2,500
New +$739K
ABUS icon
227
CALL
Arbutus Biopharma
ABUS
$845M
$779K 0.03%
+657
New +$10K
ZSPH
228
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
$778K 0.03%
+14,848
New +$731K
CYTK icon
229
PUT
Cytokinetics
CYTK
$10.6B
$768K 0.03%
+1,143
New +$7.5K
BDSI
230
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$765K 0.03%
96,100
+58,800
+158% +$505K
VIRX
231
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$738K 0.03%
1,167
-142
-11% -$75.5K
NURO
232
DELISTED
NeuroMetrix, Inc. Common Stock
NURO
$727K 0.03%
312
+151
+94% +$454K
NXTM
233
DELISTED
NxStage Medical Inc.
NXTM
$722K 0.03%
+50,542
New +$856K
ACGN
234
CALL
DELISTED
Aceragen Inc
ACGN
$714K 0.03%
+14
New +$6.42K
TLPH icon
235
CALL
Talphera
TLPH
$68M
$703K 0.03%
83
+7
+9% +$547
JUNO
236
PUT
DELISTED
Juno Therapeutics, Inc.
JUNO
$693K 0.03%
+130
New +$6.9K
BLCM
237
PUT
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$691K 0.03%
+33
New +$8.09K
FOCL
238
PUT
EDAP TMS S.A.
FOCL
$234M
$670K 0.02%
2,061
-626
-23% -$2.05K
RMTI icon
239
PUT
Rockwell Medical
RMTI
$27.6M
$664K 0.02%
+4
New +$5.08K
AMRN
240
CALL
Amarin Corp
AMRN
$298M
$658K 0.02%
+134
New +$6.03K
TTHI
241
DELISTED
TRANSITION THERAPEUTICS INC (CANADA)
TTHI
$636K 0.02%
302,837
+34,437
+13% +$241K
BDSI
242
PUT
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$628K 0.02%
789
-196
-20% -$1.68K
KITE
243
PUT
DELISTED
Kite Pharma, Inc.
KITE
$622K 0.02%
102
+4
+4% +$228
RNVA
244
DELISTED
Rennova Health, Inc.
RNVA
$610K 0.02%
196
-4
-2% -$15K
TLPH icon
245
Talphera
TLPH
$68M
$605K 0.02%
7,135
-3,311
-32% -$259K
JUNO
246
DELISTED
Juno Therapeutics, Inc.
JUNO
$604K 0.02%
+11,333
New +$602K
TPST icon
247
PUT
Tempest Therapeutics
TPST
$14.1M
– –
0
– –
CBPO
248
DELISTED
China Biologic Products Holdings, Inc.
CBPO
$576K 0.02%
+5,000
New +$525K
PTCT icon
249
PUT
PTC Therapeutics
PTCT
$6.17B
$573K 0.02%
+119
New +$6.94K
GEVO icon
250
Gevo
GEVO
$358M
$572K 0.02%
+438
New +$585K
8 9
10
11 12

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AB
Aozora Bank Tokyo, Japan $43.6M AUM 1.15% 1-Year Est. Return

Sabby Management's Q2 2015 Portfolio in Review

As of Q2 2015, Sabby Management held 404 positions worth $2.74B, up 14% from $2.4B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Sabby Management withdrew a net $310M in Q2 2015, closing 88 positions and reducing 80 holdings. Its most notable exit was Allergan plc, an estimated $33.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 8.3% of assets, down from 9.4% a quarter earlier, followed by Energy and Technology.

Against the trend, Sabby Management opened a new position in ExxonMobil worth $14.8M.

  • Sabby Management's largest Q2 2015 buy was ExxonMobil: 178,310 shares worth $14.8M.
  • Sabby Management added most to iShares 20+ Year Treasury Bond ETF in Q2 2015, an estimated $23.4M increase.
  • Sabby Management's biggest Q2 2015 reduction was Tempest Therapeutics, cutting an estimated $53.9M.
  • Sabby Management fully exited Allergan plc in Q2 2015, selling an estimated $33.8M.
  • Sabby Management's ten largest holdings make up 45% of its $2.74B portfolio in Q2 2015.
  • Sabby Management opened 120 new positions and closed 88 in Q2 2015.
  • Sabby Management's portfolio value rose 14% quarter-over-quarter to $2.74B.

Based on Sabby Management's 13F filing for Q2 2015, filed 14 Aug 2015.